Value
6.0/10data confidence 60%| Component | Sub-score |
|---|---|
| P/E | 9.2 |
| P/S | 3.1 |
| EV/EBITDA | 5.8 |
APMD · Why this verdict
Why Apnimed (APMD) is rated DATA_ISSUE
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictDATA_ISSUE
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Per-dimension breakdown
Quality
6.9/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 6.7 |
| Moat | 7.0 |
| Piotroski F | 7.8 |
- ▸Strong Piotroski F-Score: 7/9
Growth
5.0/10data confidence 50%Momentum
5.0/10data confidence 50%Sentiment
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
Insider
8.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 8.0 |
| insider conviction | 8.0 |
- ▸Notable insider buying — $5,200,000 (0.411% of mkt cap)
Peer rank
6.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.9 |
| quality rank | 3.0 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
5.0/10data confidence 50%Risk (lower is worse)
5.0/10data confidence 50%Catalyst
5.0/10data confidence 50%How the verdict was assembled
Engine trigger
No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run.
Engine technical detail
verdict_path:
L0:DATA_ISSUE_NO_PRICEPassed (7)
- MOMENTUM:5.0>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- MOMENTUM:5.0<5.5 (soft — BUY_NOW allowed but watch)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
0.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The DATA_ISSUE verdict reflects clean gate clearance against Insider at 8.0 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 8.0, Quality at 6.9, and Value at 6.0; the weakest are Catalyst at 5.0, Risk (lower is worse) at 5.0, and Technical at 5.0. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.